Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.93 USD | +0.58% | -.--% | +526.50% |
May. 24 | Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index | CI |
May. 23 | AbbVie Completes Acquisition of Landos Biopharma | MT |
Chart calendar Landos Biopharma, Inc.
Upcoming events on Landos Biopharma, Inc.
Past events on Landos Biopharma, Inc.
2024-05-22 | Extraordinary Shareholders Meeting |
2024-03-21 08:00 am | Q4 2023 Earnings Release |
2024-02-22 | European Crohn and Colitis Organisation Congress - Poster number: P739 |
2024-02-22 | European Crohn and Colitis Organisation Congress - Poster number: P144 |
2024-02-22 | European Crohn and Colitis Organisation Congress - Poster number: P114 |
2024-02-22 | European Crohn and Colitis Organisation Congress - Poster number: P571 |
2024-02-22 | European Crohn and Colitis Organisation Congress - Poster number: P086 |
2024-02-22 | European Crohn and Colitis Organisation Congress - Poster number: P077 |
2023-11-09 08:00 am | Q3 2023 Earnings Release |
2023-10-24 01:30 pm | American College of Gastroenterology Scientific Meeting - Poster Number : P3644 |
2023-10-24 01:30 pm | American College of Gastroenterology Scientific Meeting - Poster Number : P3548 |
2023-10-24 01:30 pm | American College of Gastroenterology Scientific Meeting - Poster Number : P3607 |
2023-10-16 08:30 am | United European Gastroenterology Conference - The new kids on the block in IBD: Part 2 |
2023-10-16 05:30 am | United European Gastroenterology Conference - The new kids on the block in IBD: Part 1 |
2023-08-09 08:00 am | Q2 2023 Earnings Release |
2023-06-09 09:00 am | Jefferies Healthcare Conference |
2023-05-23 09:00 am | Annual General Meeting |
2023-05-12 08:00 am | Q1 2023 Earnings Release |
2023-03-23 08:00 am | Q4 2022 Earnings Release |
2023-02-28 | ECCO Congress |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 18,0 18,0 0% | 0,00 0,00 - | 0,00 0,00 - |
EBITDA Million USD | Released Forecast Spread | 0,00 | -30,5 -28,0 -9.07% | -38,6 -30,0 -28.73% | 0,00 0,00 - | 0,00 0,00 - |
EBIT Million USD | Released Forecast Spread | -13,3 | -30,7 -25,7 -19.35% | -38,8 -32,3 -20.1% | -40,6 -42,0 3.43% | 0,00 0,00 - |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -30,1 -25,0 -20.39% | -38,4 -33,3 -15.33% | -39,3 -41,8 6.05% | 0,00 0,00 - |
Net income Million USD | Released Forecast Spread | 0,00 | -30,1 -25,0 -20.39% | -38,4 -33,2 -15.74% | -39,3 -41,8 6.04% | -21,9 -21,4 -2.5% |
EPS USD | Released Forecast Spread | -21,6 | -24,7 -20,8 -19.04% | -10,2 -8,96 -13.84% | -9,80 -9,83 0.34% | -3,50 -3,41 -2.64% |
Announcement Date | 24/07/20 | 31/03/21 | 24/03/22 | 23/03/23 | 21/03/24 |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - |
EBIT Million USD | Released Forecast Spread | -15,0 -14,9 -0.57% | -11,3 -15,0 24.98% | -7,83 -11,5 32.03% | -6,51 -7,98 18.34% | -6,48 -7,00 7.44% | -9,30 -5,50 -69% | |||
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,9 -15,4 3.38% | -11,3 -14,6 22.56% | -7,90 -11,5 31.14% | -5,23 -7,93 34.03% | -6,03 -7,00 13.8% | -8,90 -5,50 -61.76% | |||
Net income Million USD | Released Forecast Spread | -14,9 -15,4 3.38% | -11,3 -14,6 22.56% | -7,90 -11,4 30.8% | -5,23 -7,89 33.67% | -6,03 -7,00 13.8% | -3,92 -6,60 40.58% | -5,86 -4,90 -19.59% | -6,12 -5,60 -9.27% | -8,90 -5,50 -61.76% |
EPS USD | Released Forecast Spread | -3,70 -3,47 -6.54% | -2,80 -3,65 23.29% | -2,00 -2,83 29.41% | -1,30 -1,70 23.53% | -0,90 -1,00 10% | -0,63 -1,10 42.73% | -0,94 -0,79 -18.99% | -1,84 -0,91 -102.2% | -1,43 -0,88 -62.5% |
Announcement Date | 12/05/22 | 11/08/22 | 10/11/22 | 23/03/23 | 12/05/23 | 09/08/23 | 09/11/23 | 21/03/24 | 09/05/24 |
2024-07-15 01:45 am | ADDLIFE AB: Q2 2024 Earnings Release |
2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release (Projected) |
2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
2024-07-25 01:00 am | BACHEM HOLDING AG: Q2 2024 Earnings Release |
2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
2024-07-26 01:00 am | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Landos Biopharma, Inc.
2024-05-29 04:01 pm | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
2024-05-23 07:00 am | CUREVAC N.V.: Q1 2024 Earnings Release |
2024-05-22 01:00 am | EVOTEC SE: Q1 2024 Earnings Release |
2024-05-21 05:14 pm | ALVOTECH: Q1 2024 Earnings Release |
2024-05-21 07:00 am | EXSCIENTIA PLC: Q1 2024 Earnings Release |
2024-05-17 02:00 am | BIOARCTIC AB: Q1 2024 Earnings Release |
2024-05-15 04:05 pm | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-15 07:00 am | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
2024-05-14 04:05 pm | KYVERNA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
- Stock Market
- Equities
- LABP Stock
- Calendar Landos Biopharma, Inc.